Brief: Mesoblast Files For FDA Designations In Congenital Heart Disease

Mesoblast

27/11/2023 01:24

Nov 27 (Reuters) - Mesoblast Ltd  MSB.AX :
    * FILES FOR FDA DESIGNATIONS IN CONGENITAL HEART DISEASE
    * FILED FOR ORPHAN DRUG DESIGNATION AND RARE PEDIATRIC
DISEASE
DESIGNATION WITH UNITED STATES FDA

Source text for Eikon:  ID:nASX2JwFBt 
Further company coverage:  MSB.AX 

 ((Reuters.Briefs@thomsonreuters.com;))